Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine + R-GDP versus R-CHOP in interim PET-positive newly diagnosed DLBCL
ChiCTR2000035106Phase 2Recruiting
- Sponsor
- Union Hospital of Huazhong University of Science and Technology
- Start
- Jul 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of decitabine, rituximab, gemcitabine, cisplatin, dexamethasone and 4 more in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Union Hospital of Huazhong University of Science and Technology. Primary endpoints: Complete response, Partial response and 1 more. Started Jul 2020; status: recruiting.
02
Drugs
decitabinerituximabgemcitabinecisplatindexamethasone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2000035106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035106.